# A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Deuremidevir Hydrobromide for Suspension

> **NCT06328400** · PHASE1 · COMPLETED · sponsor: **Vigonvita Life Sciences** · enrollment: 24 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **DRUG:** Deuremidevir Hydrobromide for Suspension
- **DRUG:** Deuremidevir Hydrobromide for Suspension Placebo

## Key facts

- **NCT ID:** NCT06328400
- **Lead sponsor:** Vigonvita Life Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-27
- **Primary completion:** 2024-05-06
- **Final completion:** 2024-05-06
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06328400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06328400, "A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Deuremidevir Hydrobromide for Suspension". Retrieved via AI Analytics 2026-09-16 from https://api.ai-analytics.org/clinical/NCT06328400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*